Immunovant, Inc.
General ticker "IMVT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.9B (TTM average)
Immunovant, Inc. follows the US Stock Market performance with the rate: 25.8%.
Estimated limits based on current volatility of 2.5%: low 22.20$, high 23.34$
Factors to consider:
- Total employees count: 207 (+26.2%) as of 2024
- Top business risk factors: Product quality issues, Senior management turnover, Strategic risks and growth management, Geopolitical risks, Regulatory and compliance
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-03-31 to 2027-03-31
- 2025-03-31 to 2026-03-31 estimated range: [10.31$, 26.42$]
- 2026-03-31 to 2027-03-31 estimated range: [8.68$, 22.33$]
Financial Metrics affecting the IMVT estimates:
- Negative: with PPE of -6.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -13.28 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of -0.03 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 91.14 > 63.39
Short-term IMVT quotes
Long-term IMVT plot with estimates
Financial data
| YTD | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $208.28MM | $270.21MM | $438.15MM |
| Operating Income | $-208.28MM | $-270.21MM | $-438.15MM |
| Non-Operating Income | $-2.67MM | $11.44MM | $25.20MM |
| Interest Expense | $12.48MM | $0.00MM | $0.00MM |
| R&D Expense | $160.26MM | $212.93MM | $360.92MM |
| Income(Loss) | $-210.95MM | $-258.77MM | $-412.95MM |
| Taxes | $0.01MM | $0.57MM | $0.89MM |
| Profit(Loss)* | $-210.96MM | $-259.34MM | $-413.84MM |
| Stockholders Equity | $362.49MM | $617.76MM | $707.45MM |
| Assets | $405.84MM | $666.37MM | $776.22MM |
| Operating Cash Flow | $-188.19MM | $-214.23MM | $-375.87MM |
| Capital expenditure | $0.20MM | $0.36MM | $0.76MM |
| Investing Cash Flow | $-0.20MM | $-0.36MM | $-0.76MM |
| Financing Cash Flow | $70.89MM | $472.43MM | $454.49MM |
| Earnings Per Share** | $-1.71 | $-1.88 | $-2.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.